First Republic Investment Management, Inc. Akebia Therapeutics, Inc. Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$2.92 - $5.06 $50,332 - $87,219	-17,237 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $10,056 - $17,123	-4,530 Reduced 20.81%	17,237 $48,000
Q3 2020 Nov 12, 2020	SELL	$2.39 - $13.08 $1,974 - $10,804	-826 Reduced 3.66%	21,767 $55,000
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $566 - $1,154	85 Added 0.38%	22,593 $307,000
Q1 2020 May 13, 2020	BUY	$4.1 - $10.24 $20,237 - $50,544	4,936 Added 28.09%	22,508 $171,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $666 - $1,420	-211 Reduced 1.19%	17,572 $111,000
Q3 2019 Nov 08, 2019	BUY	$3.55 - $5.4 $19,116 - $29,079	5,385 Added 43.43%	17,783 $70,000
Q2 2019 Aug 07, 2019	SELL	$4.1 - $8.05 $520 - $1,022	-127 Reduced 1.01%	12,398 $60,000
Q1 2019 Apr 30, 2019	BUY	$5.41 - $8.73 $1,103 - $1,780	204 Added 1.66%	12,525 $103,000
Q4 2018 Feb 12, 2019	BUY	$5.39 - $9.15 $66,410 - $112,737	12,321 New	12,321 $68,000

Others Institutions Holding AKBA

# of Institutions

121

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

Black Rock Inc. New York, NY

11.6M
Shares

$20.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$18 Million
0.0% of portfolio
Satter Management Co., L.P.

5.75M
Shares

$10.3 Million
13.23% of portfolio
Geode Capital Management, LLC Boston, MA

4.75M
Shares

$8.51 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

3.72M
Shares

$6.65 Million
0.01% of portfolio

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account